Nothing Special   »   [go: up one dir, main page]

NO20015932L - Fremgangsmåte til å behandle diabetes - Google Patents

Fremgangsmåte til å behandle diabetes

Info

Publication number
NO20015932L
NO20015932L NO20015932A NO20015932A NO20015932L NO 20015932 L NO20015932 L NO 20015932L NO 20015932 A NO20015932 A NO 20015932A NO 20015932 A NO20015932 A NO 20015932A NO 20015932 L NO20015932 L NO 20015932L
Authority
NO
Norway
Prior art keywords
type
diabetes
symptoms
procedures
treating diabetes
Prior art date
Application number
NO20015932A
Other languages
English (en)
Other versions
NO324117B1 (no
NO20015932D0 (no
Inventor
Andreas Sommer
Original Assignee
Celtrix Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharma filed Critical Celtrix Pharma
Publication of NO20015932D0 publication Critical patent/NO20015932D0/no
Publication of NO20015932L publication Critical patent/NO20015932L/no
Publication of NO324117B1 publication Critical patent/NO324117B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
NO20015932A 1999-06-04 2001-12-04 Anvendelse av et kompleks omfattende IGF-I/IGFBP-3 til a fremstille et legemiddel til a behandle diabetes. NO324117B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/326,189 US6040292A (en) 1999-06-04 1999-06-04 Methods for treating diabetes
PCT/US2000/014163 WO2000074710A2 (en) 1999-06-04 2000-05-23 Methods for treating diabetes

Publications (3)

Publication Number Publication Date
NO20015932D0 NO20015932D0 (no) 2001-12-04
NO20015932L true NO20015932L (no) 2002-01-31
NO324117B1 NO324117B1 (no) 2007-08-27

Family

ID=23271175

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015932A NO324117B1 (no) 1999-06-04 2001-12-04 Anvendelse av et kompleks omfattende IGF-I/IGFBP-3 til a fremstille et legemiddel til a behandle diabetes.

Country Status (16)

Country Link
US (1) US6040292A (no)
EP (1) EP1183042B1 (no)
JP (1) JP2003501397A (no)
KR (1) KR100694737B1 (no)
CN (1) CN1235637C (no)
AT (1) ATE271880T1 (no)
AU (1) AU780400B2 (no)
CA (1) CA2373281C (no)
DE (1) DE60012517T2 (no)
ES (1) ES2222208T3 (no)
HK (1) HK1044895A1 (no)
IL (1) IL146868A0 (no)
MX (1) MXPA01013384A (no)
NO (1) NO324117B1 (no)
WO (1) WO2000074710A2 (no)
ZA (1) ZA200110408B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
TR201807700T4 (tr) * 2000-07-03 2018-06-21 Squibb Bristol Myers Co Çözünür CTLA4 mutant moleküllerinin kullanımları.
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
CA2422625A1 (en) * 2000-09-19 2002-03-28 Bioexpertise, Llc Method for use of igf-binding protein for selective sensitization of target cells in vivo
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US20040077679A1 (en) * 2002-07-29 2004-04-22 Cincotta Anthony H. Therapeutic treatment for the metabolic syndrome and type 2 diabetes
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
EP1835817B1 (en) * 2004-12-30 2018-02-14 Hill's Pet Nutrition, Inc. Compositions for feline consumption
WO2008130315A1 (en) * 2007-04-18 2008-10-30 Premacure Ab Method and product for treatment and/or prevention of complications of prematurity
US8404639B2 (en) 2008-10-29 2013-03-26 The Rockefeller University Methods and kits for treating disease by administering insulin-like growth factor binding protein-2
AU2010232692C1 (en) 2009-04-01 2017-06-01 Genentech, Inc. Treatment of insulin-resistant disorders
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
TR201809456T4 (tr) * 2010-08-16 2018-07-23 Allergan Inc Alfa-2b adrenerjik reseptör agonistleri olan düzenleyici t hücrelerini aktifleştirme metodu.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200509A (en) * 1987-04-06 1993-04-06 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them; recombinant DNA molecules, hosts, processes and human somatomedin carrier protein-like polypeptides
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
NZ255461A (en) * 1992-08-20 1996-12-20 Biotechnology & Biolog Science Specific binding molecules for insulin-like-growth-factor-1 (igf-1), antigens capable of generating them and their use in enhancing igf-1 activity
US5407913A (en) * 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
AU683043B2 (en) * 1993-01-25 1997-10-30 Beth Israel Hospital Association, The Method for modifying, diagnosing, and screening for IGF-I sensitive cell barrier properties
US5563046A (en) * 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
ATE190499T1 (de) * 1993-08-03 2000-04-15 Celtrix Pharma Methode zur behandlung von reproduktionserkrankungen
CA2172158A1 (en) * 1993-09-20 1995-03-30 Joseph A. Carlino Treatment of immunologic and hematologic disorders with igfbp alone or complexed with igf
DE69431527T2 (de) * 1993-11-15 2003-06-26 Celtrix Pharmaceuticals, Inc. Verwendung von igf-1 und igfbp-3 zur herstellung eines arzneimittels zur behandlung von einer nierenerkrankung
EP0729361A4 (en) * 1993-11-15 1996-11-06 Celtrix Pharma METHOD FOR TREATING NEUROLOGICAL DISEASES
CA2195474A1 (en) * 1994-07-20 1996-02-01 Cedo Martin Bagi Igf/igfbp complex for promoting bone formation and for regulating bone remodeling
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US6436897B2 (en) * 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes

Also Published As

Publication number Publication date
CA2373281C (en) 2010-01-12
AU5041100A (en) 2000-12-28
CA2373281A1 (en) 2000-12-14
AU780400B2 (en) 2005-03-17
US6040292A (en) 2000-03-21
NO324117B1 (no) 2007-08-27
EP1183042B1 (en) 2004-07-28
IL146868A0 (en) 2002-08-14
JP2003501397A (ja) 2003-01-14
ES2222208T3 (es) 2005-02-01
KR20020020723A (ko) 2002-03-15
WO2000074710A3 (en) 2001-06-28
ZA200110408B (en) 2003-03-19
WO2000074710A2 (en) 2000-12-14
NO20015932D0 (no) 2001-12-04
CN1235637C (zh) 2006-01-11
MXPA01013384A (es) 2003-09-04
KR100694737B1 (ko) 2007-03-14
DE60012517D1 (de) 2004-09-02
DE60012517T2 (de) 2005-08-04
HK1044895A1 (en) 2002-11-08
EP1183042A2 (en) 2002-03-06
CN1387440A (zh) 2002-12-25
ATE271880T1 (de) 2004-08-15

Similar Documents

Publication Publication Date Title
NO20015932L (no) Fremgangsmåte til å behandle diabetes
PT1409006E (pt) Misturas monodispersas e métodos de tratamento de diabetes
MXPA04001525A (es) Analogos de peptido -1 similar al glucagon.
EA200300026A1 (ru) Аналоги глюкагоноподобного пептида-1
NO20010982L (no) Fremgangsmåte for å administrere insulinotropiske peptider
ATE482717T1 (de) Peptid yy (pyy) zur behandlung von glukose stoffwechselkrankheiten
MY132626A (en) CARBAZOLYL-SUBSTITUTED ETHANOLAMINES AS SELECTIVE ß-3 AGONISTS
NO20003051L (no) Metode for administrering av AspB28-humant insulin
SG127714A1 (en) Method of treating metabolic disorders, especiallydiabetes, or a disease or condition associated wi th diabetes
NO20005223L (no) Sammensetning for og behandling av inflammatrisk tarmsykdom ved administrering av N-acetylglucosamin i tykktarmen
HK1052139A1 (en) Method and composition for the treatment of adenoviral ocular infections
HK1040906A1 (en) Null igf for the treatment of cancer.
WO1999051216A3 (en) 3-pyridyloxyalkylamine or aryloxyalkylamine derivatives as cholinergic agonists
UA32295A (uk) Спосіб лікування порушень фертильності у хворих на цукровий діабет
GB9818650D0 (en) Therapeutic compounds and methods of making and using the same
UA32255A (uk) Спосіб лікування цукрового діабету
UA88862C2 (en) Glucagon-like peptide-1 analogs
UA72871C2 (uk) Засіб для лікування та профілактики цукрового діабету та спосіб лікування
CA2236269A1 (en) Selective .beta.3 adrenergic agonists

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees